Validation and characterisation of a novel peptide that binds monomeric and aggregated beta-amyloid and inhibits the formation of neurotoxic oligomers
MetadataShow full item record
This research was originally published in Barr, R. and Verdile, G. and Wijaya, L. and Morici, M. and Taddei, K. and Gupta, V. and Pedrini, S. et al. 2016. Validation and characterisation of a novel peptide that binds monomeric and aggregated beta-amyloid and inhibits the formation of neurotoxic oligomers. Journal of Biological Chemistry. 291: pp. 547-559. © the American Society for Biochemistry and Molecular Biology.
Although the formation of β-amyloid (Aβ) deposits in the brain is a hallmark of Alzheimer disease (AD), the soluble oligomers rather than the mature amyloid fibrils most likely contribute to Aβ toxicity and neurodegeneration. Thus, the discovery of agents targeting soluble Aβ oligomers is highly desirable for early diagnosis prior to the manifestation of a clinical AD phenotype and also more effective therapies. We have previously reported that a novel 15-amino acid peptide (15-mer), isolated via phage display screening, targeted Aβ and attenuated its neurotoxicity (Taddei, K., Laws, S. M., Verdile, G., Munns, S., D'Costa, K., Harvey, A. R., Martins, I. J., Hill, F., Levy, E., Shaw, J. E., and Martins, R. N. (2010) Neurobiol. Aging 31, 203–214). The aim of the current study was to generate and biochemically characterize analogues of this peptide with improved stability and therapeutic potential. We demonstrated that a stable analogue of the 15-amino acid peptide (15M S.A.) retained the activity and potency of the parent peptide and demonstrated improved proteolytic resistance in vitro (stable to t = 300 min, c.f. t = 30 min for the parent peptide). This candidate reduced the formation of soluble Aβ42 oligomers, with the concurrent generation of non-toxic, insoluble aggregates measuring up to 25–30 nm diameter as determined by atomic force microscopy. The 15M S.A. candidate directly interacted with oligomeric Aβ42, as shown by coimmunoprecipitation and surface plasmon resonance/Biacore analysis, with an affinity in the low micromolar range. Furthermore, this peptide bound fibrillar Aβ42 and also stained plaques ex vivo in brain tissue from AD model mice. Given its multifaceted ability to target monomeric and aggregated Aβ42 species, this candidate holds promise for novel preclinical AD imaging and therapeutic strategies.
Showing items related by title, author, creator and subject.
Formation and characteristics of glucose oligomers during the hydrolysis of cellulose in hot-compressed waterYu, Yun (2009)Energy production from fossil fuels results in significant carbon dioxide emission, which is a key contributor to global warming and the problems related to climate change. Biomass is recognized as an important part of ...
Bharadwaj, Prashant; Head, R.; Martins, R.; Raussens, V.; Sarroukh, R.; Jegasothy, H.; Waddington, L.; Bennett, L. (2013)A proline-rich peptide product prepared from bovine whey protein that was enriched in several hydrophobic amino acids including proline (whey proline-rich peptide, wPRP) was shown to modulate the folding pathway of human ...
Elaskalani, O.; Khan, I.; Morici, M.; Matthysen, C.; Sabale, M.; Martins, R.; Verdile, G.; Metharom, Pat (2017)© 2017 Taylor & Francis The effects of the Alzheimer’s disease (AD)-associated Amyloid-ß (Aß) peptides on platelet aggregation have been previously assessed, but most of these studies focused on Aß40 species. It also ...